SCHEMBL4877598

SCHEMBL4877598

COc1cccc(C2(C(=O)NS(=O)(=O)O)CCC(c3ccccc3)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 3/20 0.41
USP5 P45974 1/20 0.41
CFTR P13569 1/20 0.41
KMT2A Q03164 2/20 0.41
HDAC4 P56524 1/20 0.41
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
GRIN2B Q13224 2/20 0.40
ELOVL1 Q9BW60 1/20 0.40
OPRK1 P41145 1/20 0.40
MEN1 O00255 1/20 0.39
ADAM17 P78536 1/20 0.39
HTR2C P28335 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4880349 0.87 HDAC4 (0.46) OPRD1KMT2AHDAC4ALDH1A1GRIN2B
SCHEMBL4878256 0.87 ALDH1A1 (0.43) KMT2AALDH1A1ELOVL1MEN1ADAM17
SCHEMBL4877673 0.85 KMT2A (0.42) KMT2AALDH1A1GRIN2BMEN1
SCHEMBL4868377 0.84 ADAM17 (0.48) OPRD1KMT2AALDH1A1KDM4ELMNA
SCHEMBL4880013 0.84 ALDH1A1 (0.46) OPRD1KMT2AALDH1A1KDM4ELMNA
SCHEMBL4876705 0.84 OPRD1 (0.46) OPRD1KMT2AALDH1A1GRIN2BELOVL1
SCHEMBL4880460 0.81 ELOVL1 (0.43) KMT2AALDH1A1ELOVL1MEN1ADAM17
SCHEMBL4874912 0.81 L3MBTL1 (0.44) KMT2AALDH1A1LMNATSHRGRIN2B
SCHEMBL4877607 0.81 SIGMAR1 (0.42) OPRD1ALDH1A1KDM4ELMNATSHR
SCHEMBL4880538 0.81 SOAT1 (0.50) KMT2AALDH1A1KDM4ETSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096922-A1 Novel Sulfonamide derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-04-24 US disclosed
EP-1736467-A1 NOVEL SULFONAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096922-A1 Novel Sulfonamide derivative NR4A1, NR4A2, NR4A3 OPRD1 628/4885USP5 3865/4885CFTR 2070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.